Diagnosis and Management of Diabetes

Differentiating Type 1 and Type 2 Diabetes

• In overweight adolescents, C-peptide measurement may help differentiate type 1 from type 2 diabetes, with normal C-peptide levels considered to be above 1.8 ng/mL (>600 pmol/L), consistent with a type 2 diabetes pattern, as recommended by the American Diabetes Association 1

• C-peptide levels can be interpreted as follows:

  C-peptide level	Clinical interpretation
  <0.6 ng/mL (<200 pmol/L)	Type 1 diabetes pattern
  0.6-1.8 ng/mL (200-600 pmol/L)	Indeterminate status
  >1.8 ng/mL (>600 pmol/L)	Type 2 diabetes pattern

  1

• C-peptide testing is only indicated in people receiving insulin treatment, and a random C-peptide sample (with concurrent glucose) within 5 hours of eating can replace a formal C-peptide stimulation test for classification purposes, as stated by the American Diabetes Association 1
• C-peptide testing should not be performed within 2 weeks of a hyperglycemic emergency, and is not recommended for routine screening for diabetes or cardiovascular disease risk, as stated by the American Diabetes Association 1, 2

Diagnosis of Special Cases

• In patients with checkpoint inhibitor-associated diabetes, diagnosis includes new-onset hyperglycemia with low C-peptide (<0.4 nmol/L) indicating absolute insulin deficiency 3
• Hypoglycemia with elevated C-peptide should be evaluated for insulinoma or other causes of endogenous hyperinsulinism, with an insulin level >3 mcIU/mL (usually >6 mcIU/mL) when blood glucose is <40-45 mg/dL, with an insulin-to-glucose ratio ≥0.3 indicating inappropriate insulin secretion, according to the National Comprehensive Cancer Network 4
• Proton pump inhibitor use can cause spuriously elevated chromogranin A levels, often measured alongside C-peptide in suspected insulinoma, according to the National Comprehensive Cancer Network 4

Stages of Type 1 Diabetes

• The stages of type 1 diabetes can be summarized as follows:

  Stage	Characteristics	Diagnostic Findings
  Stage 1	Autoimmunity with normoglycemia	Multiple islet autoantibodies, normal glucose levels
  Stage 2	Autoimmunity with dysglycemia	Islet autoantibodies, impaired fasting glucose or glucose tolerance
  Stage 3	Overt hyperglycemia	Autoantibodies may persist, diabetes by standard criteria

  5

Diagnosis of LADA

• The primary test for diagnosing LADA is glutamic acid decarboxylase antibody (GADA) testing, which should be performed in standardized clinical laboratories with established quality control programs, as recommended by the American Diabetes Association 2, 6

Management of Diabetes

• Initial therapy for patients with a C-peptide level of 1.9 ng/mL can focus on non-insulin approaches, including lifestyle modifications, oral hypoglycemic agents, and GLP-1 receptor agonists or other newer agents as appropriate, although insulin therapy may be needed later if beta-cell function declines, with the American Diabetes Association recommending reserving insulin therapy for cases of significant hyperglycemia not controlled with oral agents 1, 7, 8
• Early insulin therapy is recommended to preserve beta-cell function in LADA patients, as suggested by the American Diabetes Association, with a starting total daily insulin requirement of 0.3-0.4 units/kg/day, divided into half basal insulin and half prandial insulin, as recommended by the American Family Physician and American Diabetes Association 2, 9, 10
• Regular monitoring of glycemic control with HbA1c every 3 months, and periodic reassessment of C-peptide levels to track disease progression, is recommended by the American College of Clinical Endocrinologists and American Diabetes Association, with C-peptide measurement helping assess remaining beta-cell function, and values <1.51 ng/mL having 96% negative predictive value for type 1 diabetes 11, 9
• The American Heart Association suggests vigilant monitoring for complications, including cardiovascular risk factors and kidney disease, and considering SGLT2 inhibitors for patients with these conditions, with regular assessment of glycemic control and C-peptide levels necessary to track disease progression, as recommended by current guidelines 7, 6
• The American Diabetes Association recommends diabetes self-management education, including skills such as responding to hypoglycemia, anticipating exercise effects, monitoring for diabetic ketoacidosis, and carbohydrate counting, to empower patients and improve outcomes, with regular reassessment of glycemic control and vigilant monitoring for complications essential for patients with low C-peptide levels 10, 12, 13